NAV

FM-VP4

Identification

Generic Name
FM-VP4
DrugBank Accession Number
DB05449
Background

FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species. Additional experiments suggest that FM-VP4 can reduce plasma LDL cholesterol levels and triglyceride levels, reduce weight gain and exert a anti-atherosclerosis effect.

Type
Small Molecule
Groups
Investigational
Synonyms
  • Disodium ascorbyl phytostanol phosphates
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in hyperlipidemia and cancer/tumors (unspecified).

Monotherapy is recommended for people with marginally high LDL-cholesterol or who cannot be prescribed statins due to drug interactions and safety concerns. Combination Therapy is recommended if statin therapy alone is either insufficient to achieve the guidelines set by the NCEP or there is concern over side effects as Statin doses can be lowered in combination treatment without losing efficacy.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

FM VP4 is thought to bind competitively with cholesterol to MDR1 resulting in a synergistic decrease in cholesterol accumlation. Others have suggested that FM VP4 may act by inhibiting a transporter that mediates intestinal absorption of cholesterol.

Mechanism of action

FM VP4 is thought to bind competitively with cholesterol to MDR1 resulting in a synergistic decrease in cholesterol accumlation. Others have suggested that FM VP4 may act by inhibiting a transporter that mediates intestinal absorption of cholesterol. One study indicates that FM-VP4 inhibits cholesterol accumulation within IEC-6 cells and is most effective at equimolar concentrations with cholesterol, further suggesting that the action of FM-VP4 is likely at the cell surface and not elicited intracellularly.

TargetActionsOrganism
UP-glycoprotein 1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Clinical trials have indicated that the drug is well-tolerated.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1PHN4US15Q
CAS number
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Thornton SJ, Warburton C, Wasan KM, Kozlowski P: Treatment with a cholesterol absorption inhibitor (FM-VP4) reduces body mass and adipose accumulation in developing and pre-obese mice. Drug Dev Ind Pharm. 2007 Oct;33(10):1058-69. [Article]
  2. Burnett JR, Huff MW: Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs. 2006 Nov;15(11):1337-51. [Article]
  3. Looije NA, Risovic V, Stewart DJ, Debeyer D, Kutney J, Wasan KM: Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci. 2005 Aug 24;8(3):400-8. [Article]
  4. Jia X, Ebine N, Wang Y, Awad AB, Jones PJ: Effects of different phytosterol analogs on colonic mucosal cell proliferation in hamsters. J Nutr Biochem. 2006 Jun;17(6):396-401. Epub 2005 Sep 26. [Article]
  5. Ebine N, Jia X, Demonty I, Wang Y, Jones PJ: Effects of a water-soluble phytostanol ester on plasma cholesterol levels and red blood cell fragility in hamsters. Lipids. 2005 Feb;40(2):175-80. [Article]
  6. Ng AW, Lukic T, Pritchard PH, Wasan KM: Development and characterization of liposomal disodium ascorbyl phytostanyl phosphates (FM-VP4). Drug Dev Ind Pharm. 2004 Aug;30(7):739-58. [Article]
  7. Wasan KM, Choo E, Sivak O, Wallis S, Letchford K, Burt HM, Stewart DJ, Lukic T: Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure. Drug Dev Ind Pharm. 2004 Aug;30(7):725-30. [Article]
  8. Burnett JR: FM-VP4 Forbes Medi-Tech. Curr Opin Investig Drugs. 2003 Sep;4(9):1120-5. [Article]
  9. Ng AW, Lukic T, Pritchard PH, Wasan KM: Development of novel water-soluble phytostanol analogs: disodium ascorbyl phytostanyl phosphates (FM-VP4): preclinical pharmacology, pharmacokinetics and toxicology. Cardiovasc Drug Rev. 2003 Fall;21(3):151-68. [Article]
  10. Wasan KM, Yau E, Boulanger KD, Ramswamy M, Pritchard PH: Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells. AAPS PharmSci. 2003;5(1):E6. [Article]
  11. Lukic T, Wasan KM, Zamfir D, Moghadasian MH, Pritchard PH: Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism. 2003 Apr;52(4):425-31. [Article]
  12. Wasan KM, Zamfir C, Pritchard PH, Pederson RA: Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. J Pharm Sci. 2003 Feb;92(2):281-8. [Article]
  13. Ramaswamy M, Yau E, Wasan KM, Boulanger KD, Li M, Pritchard PH: Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharm Pharm Sci. 2002 Jan-Apr;5(1):29-38. [Article]
  14. Wasan KM, Najafi S, Peteherych KD, Pritchard PH: Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. J Pharm Sci. 2001 Nov;90(11):1795-9. [Article]
  15. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH: Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci. 2001 Sep-Dec;4(3):228-34. [Article]
  16. Wasan KM, Peteherych KD, Najafi S, Zamfir C, Pritchard PH: Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4, following administration to rats. J Pharm Pharm Sci. 2001 Sep-Dec;4(3):207-16. [Article]
PubChem Substance
347910145

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHigh Cholesterol1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52